Table 1. Baseline Characteristics of the Study Patientsa.
| Characteristic | Antidepressant group (n = 215) | No antidepressant group (n = 919) | Standardized difference |
|---|---|---|---|
| Age group, y | |||
| 66-69 | 48 (22.3) | 177 (19.3) | 0.0756 |
| 70-79 | 83 (38.6) | 390 (42.4) | 0.0781 |
| ≥80 | 84 (39.1) | 352 (38.3) | 0.0158 |
| Sex | |||
| Female | 117 (54.4) | 422 (45.9) | 0.1706 |
| Male | 98 (45.6) | 497 (43.8) | 0.1706 |
| Rural home address | 23 (10.7) | 105 (11.4) | 0.0216 |
| Charlson Comorbidity Index, mean (SD)b | 2.3 (2.1) | 2.0 (2.1) | 0.1200 |
| eGFR, mean (SD), mL/min/1.73 m2c | 70.7 (28.3) | 69.6 (27.2) | 0.0393 |
| History of substance use disorder | ≤5 | ≤5 | 0.0221 |
| Days of linezolid treatment, mean (SD) | 11.7 (7.2) | 10.3 (6.2) | 0.2089 |
| No. of antidepressants, mean (SD) | 1.2 (0.5) | 0 | 3.8008 |
| Taking other serotonergic medication(s) | 19 (8.8) | 47 (5.1) | 0.1465 |
Abbreviation: eGFR, estimated glomerular filtration rate.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Data available for 175 patients in the antidepressant group and 760 patients in the no antidepressant group.
c
Data available for 208 patients in the antidepressant group and 897 patients in the no antidepressant group.